DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2227756/can-rigel-pharmaceuticals-rigl-beat-q4-earnings-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227756 Feb 19, 2024 - Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth. 0

https://www.zacks.com/stock/news/2228601/sarepta-therapeutics-srpt-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228601 Feb 20, 2024 - Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2233462/sarepta-therapeutics-srpt-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2233462 Feb 28, 2024 - The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2234137/sarepta-srpt-q4-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2234137 Feb 29, 2024 - Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys. 0

https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001 Mar 13, 2024 - The threat is still emerging, but it could be significant. 0

https://www.zacks.com/stock/news/2263473/what-s-in-store-for-puma-biotechnology-pbyi-in-q1-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2263473 Apr 26, 2024 - On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx. 0

https://www.zacks.com/stock/news/2264391/moderna-mrna-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2264391 Apr 29, 2024 - Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings. 0

https://www.zacks.com/stock/news/2265282/biontech-bntx-to-report-q1-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2265282 Apr 30, 2024 - On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over. 0

https://www.zacks.com/stock/news/2266535/sarepta-therapeutics-srpt-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266535 May 01, 2024 - Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2229472/sarepta-srpt-to-report-q4-earnings-will-it-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2229472 Feb 21, 2024 - Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings. 0